| 9/30/2020 | Considerations for the Use of Real-World Evidence to Assess the Effectiveness of Preventive Vaccines Recordings |
| 9/30/2020 | September 25, 2020 Approval Letter - IXINITY |
| 9/29/2020 | September 28, 2020 Approval Letter - ALBAcyte |
| 9/28/2020 | September 25, 2020 Approval Letter - VAXELIS |
| 9/25/2020 | September 25, 2020 Approval Letter - PNEUMOVAX 23 |
| 9/24/2020 | Influenza Vaccine for the 2020-2021 Season |
| 9/23/2020 | 2020 Biological License Application Supplement Noteworthy Approvals |
| 9/23/2020 | 2020 Biological Device Application Approvals |
| 9/21/2020 | Countering Bioterrorism and Emerging Infectious Diseases |
| 9/17/2020 | Influenza Vaccine for the 2020-2021 Season |
| 9/17/2020 | September 15, 2020 Approval Letter - ProQuad |
| 9/16/2020 | September 15, 2020 Approval Letter - VARIVAX |
| 9/10/2020 | Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2020 |
| 9/10/2020 | September 9, 2020 Approval Letter - ODACTRA |
| 9/10/2020 | Influenza Vaccine for the 2020-2021 Season |
| 9/8/2020 | September 3, 2020 Untitled Letter - Laguna Beach Aesthetics, Cosmetic Dermatology and Laser Center, PC |
| 9/8/2020 | eSubmitter Application History |
| 9/3/2020 | Influenza Vaccine for the 2020-2021 Season |
| 9/2/2020 | Recommendations for Investigational COVID-19 Convalescent Plasma |
| 9/2/2020 | Investigational COVID-19 Convalescent Plasma; Guidance for Industry |
| 9/2/2020 | Complete List of Licensed Products and Establishments |
| 9/2/2020 | Complete List of Substantially Equivalent 510(k) Device Applications |
| 9/2/2020 | Complete List of Currently Approved Premarket Approvals (PMAs) |
| 9/2/2020 | Complete List of Currently Approved NDA and ANDA Application Submissions |
| 8/27/2020 | Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Announcement |
| 8/27/2020 | August 27, 2020 Approval Letter - Afluria |
| 8/27/2020 | Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry |
| 8/26/2020 | Influenza Vaccine for the 2020-2021 Season |
| 8/26/2020 | Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components; Guidance for Industry |
| 8/23/2020 | Coronavirus (COVID-19) | CBER-Regulated Biologics |
| 8/23/2020 | Recommendations for Investigational COVID-19 Convalescent Plasma |
No hay comentarios:
Publicar un comentario